BetterLife Pharma Inc. has announced the appointment of Daniel Carcillo as corporate advisor to advance the development of BETR-001, the company's proprietary non-hallucinogenic derivative of LSD focused on treating traumatic brain injury, cluster headache, and migraine. This appointment represents a significant strategic move in the emerging field of neurological treatment development, particularly for conditions affecting athletes, veterans, and others suffering from brain trauma.
Carcillo brings unique firsthand experience to this role, having been forced to retire from professional hockey at age 30 due to Post Concussion Syndrome after sustaining seven concussions during his NHL career. Following his retirement in 2015, he created a non-profit organization assisting former NHL players suffering from post-concussion syndrome and mental health issues. He previously founded and served as CEO of Wesana Health, a life sciences company leveraging psilocybin-based medicine to treat traumatic brain injuries.
The significance of this appointment lies in the growing recognition of traumatic brain injury as a major public health concern affecting millions worldwide. Carcillo stated, "Joining BetterLife feels like the natural next step in my mission to help concussion survivors because we are advancing a medicine that carries the promise of psychedelic healing without the regulatory barriers and with all the serotonergic benefits people desperately need. I have lived the impact of brain trauma and I know how powerful these breakthroughs can be."
BetterLife's BETR-001 represents a novel approach in neurological treatment development. The compound is currently in preclinical and IND-enabling studies and is unique in being both non-hallucinogenic and non-controlled, allowing for potential self-administration without the regulatory hurdles typically associated with psychedelic compounds. The company's synthesis patent for BETR-001 eliminates regulatory barriers, while its pending patent for composition and method of use covers treatment of various neurological disorders until approximately 2042.
Dr. Ahmad Doroudian, CEO of BetterLife, commented on the appointment, "We are very excited to have Mr. Carcillo joining our advisory group. His firsthand experience with TBI and his passion to advance the development of medicines and treatments for those injuries will provide us with invaluable guidance." The collaboration aims to accelerate development of treatments that could potentially benefit not only professional athletes but also military veterans and anyone living with the consequences of concussion and brain trauma.
This development comes at a critical time when awareness of long-term neurological damage from repeated head trauma is increasing across contact sports and military service. The potential impact of successful development could revolutionize treatment approaches for conditions that currently have limited therapeutic options. For further information, please visit https://www.betterlifepharma.com.
